- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02086864
A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD
A Randomized, Double Blind, Placebo Controlled Study of Homeopathic Treatment of Children and Youth With Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder (ADHD) is a developmental disorder that presents during childhood, with at least some symptoms causing impairment before the age of seven. It is characterized by developmentally inappropriate levels of inattention and/or hyperactive-impulsive behavior, with significant impairment occurring in at least two settings. It affects approximately 5.2 million children in the United States. Homeopathic treatment has been shown to be a promising intervention for ADHD, however the reasons for that effectiveness is unclear. Specifically, it is unclear whether improvement is due to the homeopathic medicine, the consultative process, or other non-specific effects.
This study has 3 primary objectives: 1. to determine if there are any specific effects of homeopathic medicines in the treatment of ADHD, 2. to determine if there any specific effects the homeopathic consultation alone in the treatment of ADHD, and 3. to determine if there is an overall effect of homeopathic treatment (homeopathic medicines plus consultation) in the treatment of ADHD.
This is a three arm study. Participants will be randomized to one of three arms:
Arm 1 (Verum group): a treatment arm where the participant will receive homeopathic consultation plus a homeopathic remedy Arm 2 (Placebo group): a treatment arm where the participant will receive homeopathic consultation plus a placebo remedy Arm 3 (Usual care group): participants will continue with usual care and will not receive homeopathic treatment as part of the study.
Participants enrolled in this study, regardless of which study Arm they are in, may continue with all conventional medications or any other aspect of their current standard of care they are taking as recommended by their usual physician (so long as they are on a stable dose of the conventional ADHD medication for at least 6 weeks prior to beginning the trial). They may also continue to attend regularly scheduled visits with their own health care practitioner(s).
Participants may also start, stop or change the dose of any therapy (including conventional medications) during the study and are asked to report the change to the study team. Thus, the placebo group participants are not different than other participants, except that they will have a homeopathic consultation and a placebo remedy. The use of placebo is specific to homeopathic treatment, to allow for double-blinding, which is recognized to reduce study bias.
Prior to enrolling in the study, those considering participation will undergo a full assessment by a psychiatrist with a specialty in child and youth mental health. This assessment confirms the diagnosis and screens for inclusion/exclusion study criteria. At the same time, the psychiatrist recommends evidence-based therapies to clients including conventional medication. The psychiatrist does not directly treat the client. If medication is recommended and the clients wish to pursue it with their regular physician, they would still be able to enroll in the study if they wanted to, after six weeks of reaching a stable dose.
This study will help our understanding of the treatment process and whether different elements of the intervention have greater or lesser effects.
This study is a follow-up to an open label pilot study of the homeopathic treatment of ADHD using the same study team. Sample size was calculated based on the results of that study.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4J 1N1
- Riverdale Homeopathic Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- have a diagnosis of attention deficit hyperactivity disorder (and any of the subtypes of the diagnosis) confirmed by study psychiatrist
- have a minimum baseline score on the Connors 3 scale that is 1.5 standard deviations above the population norm based in the age and sex of the participant as was reported to be most commonly used in ADHD treatment trials
- are between 6 and 16 years of age
- are able to ingest medications in liquid or in lactose/sucrose granule form;
- if currently taking stimulant therapy for ADHD, are on a stable dose for a minimum of 6 weeks prior to beginning the study
- have an estimated I.Q. within the normal range
- have parents/guardians who are able to read and write in English
Exclusion Criteria:
- a diagnosis with an additional mental health disorder including, but not limited to, the following: Conduct Disorder, Autism Spectrum Disorder, Bipolar Disorder, and Major Depressive Disorder
- any significant suicidality
- an addiction to any substance
- taking any other prescription medication aside from a stable dose of ADHD medication
- a history of head injury (with sequelae), seizures, or organ system damage
- pregnant or lactating
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual care
|
|
Active Comparator: Individualized homeopathic medicine treatment
Participant will have a homeopathic consultation and be given a homeopathic medicine.
Homeopathic medicines are chosen from those available for sale in Canada.
|
The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada.
As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate.
Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment.
Only one remedy will be administered at a time.
Other Names:
|
Placebo Comparator: Unmedicated lactose/sucrose pill
Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Conners 3 Global Index - Parent
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Conners ADHD Index Probability score
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Change from baseline in Conners Content Scale for Inattention and Hyperactivity/Impulsivity
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Change from baseline in Conners DSM-IV-TR Symptom Scale for the ADHD Inattentive and ADHD Hyperactive-Impulsive subtypes
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Clinical Global Impression-Improvement scale
Time Frame: Week 28
|
Week 28
|
Change from baseline in the Pediatric Quality of Life Inventory
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Change from baseline in Consultation and Relational Empathy measure
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Change from baseline in RTI Provider Support Measure
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Change from baseline in the Resiliency Scales for Children & Adolescents - Mastery sub-scale
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Change from baseline in Coping Efficacy Scale
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Change from baseline in Control Beliefs Inventory - Mastery sub-scale
Time Frame: Baseline and weeks 8, 20, 28
|
Baseline and weeks 8, 20, 28
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Heather Boon, PhD, University of Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UToronto-29722
- 079-2013 (Other Identifier: Centre for Addiction and Mental Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
University Hospital Bispebjerg and FrederiksbergMental Health Services in the Capital Region, DenmarkRecruitingSleep Disturbance | Neurodevelopmental Disorders | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Attention-Deficit Hyperactivity Disorder, Unspecified Type | Attention-deficit Hyperactivity | Hyperkinetic Conduct DisorderDenmark
-
Corium, Inc.Worldwide Clinical Trials; Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Corium, Inc.Premier Research Group plc; Almac; Prometrika, LLCActive, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.Active, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Ataturk UniversityCompletedAttention-deficit/Hyperactivity DisorderTurkey
Clinical Trials on lactose/sucrose granule (Individualized homeopathic medicine treatment)
-
The Canadian College of Naturopathic MedicineCanadian CAM Research Fund; Ottawa Integrative Cancer CentreCompletedFatigue | Effects of ChemotherapyCanada
-
Charite University, Berlin, GermanyAzienda Sanitaria de Sudtirol, Hospital Meran, Meran, ItalyCompleted
-
Hospital Juarez de MexicoCompletedModerate Depression | Menopausal and Postmenopausal DisordersMexico
-
Liaoning University of Traditional Chinese MedicineMinistry of Science and Technology of the People´s Republic of ChinaCompletedCoronary Heart Disease | Stable Angina PectorisChina